BRAF and neoplasm: The use of type I BRAF inhibitors is limited to patients with tumors harboring a BRAF V600E mutation due to the risk of paradoxical activation of the MAPK pathway and accelerated tumor growth if used in patients with tumors harboring a RAF fusion, such as those involving BRAF or CRAF/RAF1 [23].